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Abstract
Background: Vascular endothelial growth factor (VEGF) is a potent angiogenic cytokine produced
physiologically by the uterus. Pathological secretion by tumours promotes growth and metastasis.
High circulating VEGF levels potentially have a deleterious effect on breast cancer by promoting
disease progression.
The aims of this study were to investigate circulating VEGF levels in breast cancer patients and
assess the effect of menopause or hysterectomy on systemic VEGF.
Methods: Patients undergoing primary surgery for breast cancer and controls matched for age,
menopausal and hysterectomy status were prospectively recruited. Serum VEGF, FSH, LH,
estrogen, progesterone and platelet levels were measured. Serum VEGF was corrected for platelet
load (sVEGFp) to provide a biologically relevant measurement of circulating VEGF. SVEGFp levels
were analyzed with respect to tumor characteristics, menopausal status and hysterectomy status.
Results: Two hundred women were included in the study; 89 breast cancer patients and 111
controls. SVEGFp levels were significantly higher in breast cancer patients compared to controls (p
= 0.0001), but were not associated with clinico-pathological tumor characteristics. Systemic VEGF
levels reduced significantly in the breast cancer patients following tumor excision (p = 0.018). The
highest systemic VEGF levels were observed in postmenopausal breast cancer patients.
Postmenopausal women who had had a previous hysterectomy had significantly higher VEGF levels
than those with an intact postmenopausal uterus (p = 0.001).
Conclusion: This study identifies an intact postmenopausal uterus as a potential means of reducing
circulating levels of VEGF which could confer a protective effect against breast cancer metastatic
potential.
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Background
Vascular Endothelial Growth Factor (VEGF) is one of the
most potent angiogenic cytokines, acting as a specific
endothelial mitogen capable of stimulating angiogenesis
in vitro and in vivo [1].
The adult female reproductive tract, under ovarian steroid
hormone influence, is the principle endogenous VEGF
producer and the only site where physiological angiogen-
esis occurs routinely. VEGF ligands and receptors are
expressed in the uterine endometrium [2] and myo-
metrium [3] and cyclical variations in serum VEGF during
the menstrual cycle have previously been demonstrated
[4,5].
VEGF is also a predominant growth factor involved in the
pathological angiogenesis that drives cancer progression
and spread [6] and serum VEGF is elevated in patients
with different tumor types, including breast cancer [7,8].
The ovarian steroid hormones estrogen and progesterone
play an important role in breast cancer development and
have been shown to influence VEGF expression in breast
cancer and non-cancer tissue, thus contributing to
tumour-derived and tumour independent circulating
VEGF levels [9-13]. Clinical studies have provided evi-
dence for a link between hormone-dependent breast can-
cer and the VEGF pathway [14-16]
The postmenopausal change in ovarian sex hormones
would be expected to alter VEGF production and subse-
quent release in the reproductive tract, and we would
expect a consequent postmenopausal change in systemic
VEGF levels. However, studies to date on the effect of
menopause on circulating VEGF and breast tumoural
VEGF have been equivocal; with conflicting reports of
increased VEGF levels in premenopausal [17] and in post-
menopausal women[18,19], or no difference in VEGF lev-
els according to menopausal status [20]. Furthermore, as
the uterus is an endogenous VEGF source, we hypothesize
that hysterectomy would also effect VEGF levels. An alter-
ation in VEGF synthesis and subsequent release would
potentially influence breast cancer cell dissemination and
response to therapy in breast cancer patients.
Our aims in this study were to investigate circulating
VEGF levels in breast cancer patients and assess the effect
of menopause or hysterectomy on systemic VEGF.
Methods
A consecutive series of patients undergoing curative sur-
gery for breast cancer over a six month period at a single
institution were invited to participate in the study.
Informed consent was obtained as approved by the Uni-
versity College Hospital Galway ethics committee. Breast
cancer patients underwent radiological investigation and
had a histological diagnosis by core biopsy. Preoperative
chest x-ray, full blood count, serum electrolytes and liver
function tests were performed in all patients. Computer-
ized tomography of chest thorax and abdomen and iso-
tope bone scan was performed selectively. No patient
received neoadjuvant cytotoxic or hormonal chemother-
apy. All surgery was performed by one of two consultant
surgeons.
A cohort of healthy, non-surgical, female volunteers was
recruited to the study during the same time period. These
women were recruited in the general surgical outpatient
clinic and had no history of malignancy or recent surgery.
At the time of recruitment all participants completed a
detailed questionnaire regarding their medical, surgical
and gynecological history. Women with a history of renal
failure, diabetes mellitus, lung disease or infectious dis-
ease were excluded from the study
Menopausal status at recruitment was defined by each
woman's reported menstrual history and ovarian function
tests. Postmenopausal women had experienced no men-
strual period for at least 12 months, had a previous bilat-
eral oopherectomy, or had postmenopausal levels of FSH
(follicle stimulating hormone), lutenizing hormone (LH)
and oestradiol. Premenopausal women were experiencing
a normal menstrual cycle. Patients who had previously
undergone a hysterectomy or were currently taking post-
menopausal hormone therapy were categorized according
to the Million Women Study protocol [21].
Peripheral venous blood samples were obtained prior to
induction of anaesthesia and at least six weeks after defin-
itive surgery. All postoperative samples were taken before
commencement of adjuvant systemic cytotoxic chemo-
therapy or radiotherapy and in the absence of residual or
metastatic disease in the study group and at the time of
recruitment in the control group.
Samples for VEGF analysis were collected in Vacutainer
SST II (serum separator tubes), transported on ice and
allowed to clot for 1 hour prior to centrifugation at 3000
r.p.m. at 4°C for 10 minutes. Serum was then separated,
aliquoted into 2 ml tubes and stored at -20°C.
Serum VEGF (sVEGF) levels were determined using a
commercially available quantitative sandwich immu-
noassay technique (Quantikine; R&D System, Minneapo-
lis, MN, USA). VEGF165  the predominant and most
biologically active isoform was measured in this study.
Briefly, a monoclonal antibody specific for VEGF165, pre-
coated onto a micro-titre plate, was used to capture the
VEGF from serum samples. An enzyme linked polyclonal
antibody specific for VEGF was added, followed by a sub-BMC Cancer 2008, 8:279 http://www.biomedcentral.com/1471-2407/8/279
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strate solution and used for quantification. All samples
were tested in duplicate. The minimal detectable dose of
VEGF was 9.0 pg/ml and maximum dose was 2000 pg/ml.
For serum samples the intra-assay variation of the assay kit
used was 4.5–6.7% and the inter-assay variation was
6.2–8.8%.
To correct for variation in platelet counts between
patients, sVEGF levels were corrected for platelet load
according to the equation sVEGF(picogram/millilitre (pg/
ml)) ÷ platelet count × 106/ml = sVEGFp (pg/106) [22]
Serum levels of FSH, LH, estradiol and progesterone were
determined using a commercially available chemilumi-
nescence assay system (ADVIA Centaur®, Bayer Diagnos-
tics, Tarreytown, NY, USA)
Statistical analysis was performed using SPSS version 14.0
software. Results are presented as median and interquar-
tile range (IQR) unless otherwise stated. The differences in
sVEGFp levels were analysed using Kruskal-Wallis or
Mann Whitney tests to compare between groups. The Wil-
coxin signed rank test was used when examining for sig-
nificant changes. Mann Whitney and Spearman's
correlation tests were used as appropriate to investigate
relationships between sVEGFp and other clinicopatholog-
ical variables. P < 0.05 was considered statistically signifi-
cant.
Results
Two hundred women were recruited to the study: 89
women who underwent curative breast cancer surgery
(study group) and 111 women with no history of malig-
nancy or recent surgery (control group).
The tumor characteristics of the breast cancer patients are
illustrated in table 1.
Among the study group there were 40 breast-conserving
procedures and 49 mastectomies performed. All proce-
dures were performed under general anaesthetic and all
patients undergoing immediate breast reconstruction (n =
14) had an additional paravertebral anaesthetic block. 58
patients had an axillary clearance and 30 had sentinel
lymph node biopsy only. One patient, with low grade
ductal carcinoma in situ (DCIS) did not have axillary
nodal evaluation.
Serum VEGF was elevated in the study group (table 2). Six
weeks following tumor resection, these levels dropped sig-
Table 1: Tumour Characteristics
Tumour Characteristic All Breast Cancers
N = 89
Premenopausal Breast Cancer
N = 25
Postmenopausal Breast Cancer
N = 64
p-value
Histologic Subtype
-Invasive Ductal (%) 67(75) 19(76) 48(75)
-Invasive Lobular (%) 12(13.5) 3(12) 9(14) 0.1
-DCIS (%) 4(4.5) 0 4(6)
-Other (%) 6(7) 3(12) 3(5)
Median tumor size (IQR) mm 25 (16–35) 28 (15–36) 24.5 (16.25–35) 0.955
Lymph node +ve (n)(%) 49 (55) 16(66) 33(52) 0.347
Receptor Status
-ER Positive (%) 78 (88) 24(96) 54(84) 0.056
-PR Positive (%) 81(91) 24(96) 57(89) 0.117
-Her2neu Positive (%) 15(17) 3(12) 12(19) 0.47
Tumor Grade
-Grade 1 (%) 19(21) 8(32) 11(17)
-Grade 2 (%) 43(48) 10(40) 33(52) 0.183
-Grade 3 (%) 27(31) 7(28) 20(31)
UICC Stage
-Stage 0 in-situ (%) 4(4) 0 4(6)
-Stage 1 (%) 19(21) 5(20) 14(22)
-Stage 2a (%) 21(24) 7(28) 14(22) 0.657
-Stage 2b (%) 26(29) 9(36) 17(27)
-Stage 3a (%) 13(15) 2(8) 11(17)
-Stage 3b (%) 6(7) 2(8) 4(6)BMC Cancer 2008, 8:279 http://www.biomedcentral.com/1471-2407/8/279
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nificantly, although they remained elevated compared to
the control group. (median pre-operative sVEGFp (IQR)
vs median post-operative sVEGFp (IQR): 1.08(0.68–1.44)
pg/106 vs 0.97(0.58–1.3) pg/106 respectively; p = 0.018)
In the premenopausal women, there was no difference in
sVEGFp levels between the study and control groups; the
highest sVEGFp levels were observed in the postmenopau-
sal breast cancer patients (Table 2).
Within the study group, sVEGF and sVEGFp were elevated
in the postmenopausal patients compared to premeno-
pausal patients.
This difference was not observed in the control group
(Table 2).
Twenty-seven (42%) of the 64 postmenopausal study
patients and 32 (47%) of the 68 postmenopausal controls
had previously had a hysterectomy for benign disease.
Postmenopausal controls who previously had a hysterec-
tomy had higher sVEGFp levels than those with an intact
uterus (median sVEGFp (IQR) hysterectomy vs intact
uterus: 1.01(0.72–1.66) pg/106 vs 0.50(0.3–1.07) pg/106
respectively; p = 0.001) (figure 1)
This difference was not seen in the study group (median
sVEGFp (IQR) hysterectomy vs intact uterus
1.11(0.95–1.28) pg/106  vs 1.11(0.77–1.55) pg/106
respectively; p = 0.43).
Serum VEGFp decreased postoperatively in the postmen-
opausal study group with an intact uterus (median
sVEGFp (IQR) preoperative vs postoperative:
1.11(0.77–1.55) pg/106  vs 0.95 (0.48–1.24) pg/106
respectively; p = 0.003). There was no significant post-
operative reduction in sVEGFp in patients who had under-
gone a previous hysterectomy (p = 0.101, figure 2a &2b)
There was no association found between sVEGFp and clin-
icopathological prognostic parameters including nodal
status (p = 0.347), tumor size (p = 0.301) and tumor grade
(p = 0.284).
sVEGFp levels in postmenopausal controls (n = 68) Figure 1
sVEGFp levels in postmenopausal controls (n = 68):  
there was a significantly higher sVEGFp level in women who 
had a previous hysterectomy (n = 32) compared to those 
with an intact postmenopausal uterus (n = 36).  * p = 0.001.
Table 2: Baseline Patient Characteristics, Serum Steroid Hormone and VEGF levels
Group Control (n = 111) Breast Cancer (n = 89)
Median age (IQR) yrs 53 (41–61) 57 (50–67)
Menopausal Status (n) Premenopausal (43) Postmenopausal (68) Premenopausal (25) Postmenopausal (64)
Median Oestrogen (IQR) pmol/l 415.5(251.5–645.2) <100 491.0(267.2–572.7) <100
Median Progesterone (IQR) nmol/l 2.5 (1.45–18.7) 1.00 (0.8–1.1) 4.7 (3.1–14.7) 0.8 (0.67–1.47)
Median sVEGF (IQR) pg/ml 117.12 (73.36–295.58) 306.67 (176.2–407.7)*
143.3(56.4–240.4) 177.8(91.9–312.9) 225.1(98.2–344.4) 326.0†(206.0–420.3)
Median sVEGFp (IQR) pg/106 0.73 (0.34–1.24) 1.08 (0.68–1.44)*
0.58 (0.26–1.16) 0.75(0.41–1.30) 0.77 (0.31–1.4) 1.11 †(0.80–1.47)
*p = 0.0001 vs Control Group levels
† p < 0.05 vs Premenopausal study group & Pre- & Postmenopausal Control Group levelsBMC Cancer 2008, 8:279 http://www.biomedcentral.com/1471-2407/8/279
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At a median follow up of 28 months there were four dis-
ease recurrences; one premenopausal patient who had
stage 3 disease at presentation developed distant metas-
tases. Three postmenopausal patients developed recur-
rence: 1 distant metastasis and 2 contralateral breast
cancers. Two of the recurrences occurred in postmenopau-
sal women who had a previous hysterectomy.
Discussion
Systemic VEGF levels are elevated in breast cancer
patients, reflecting tumour derived VEGF. The significant
decrease in circulating VEGF levels following primary exci-
sion of the tumour supports the hypothesis that tumour
derived VEGF contributes to circulating VEGF levels in
breast cancer patients.
Tumour derived VEGF drives angiogenesis and enhances
the potential for tumour growth, dissemination of malig-
nant cells and metastasis [6]. In breast cancer patients,
higher serum VEGF levels have been reported in patients
with metastatic disease compared to non-metatstatic
breast cancer patients and controls [20]. Serum VEGF has
been identified as a useful prognostic marker in malig-
nancy [23-25], however its clinical usefulness remains
questionable in breast cancer patients.
The physiological production of VEGF in the reproductive
tract contributes to circulating VEGF levels and the ovar-
ian steroid hormones have been shown to influence VEGF
expression in both uterine and breast tissue [2,9,11,26].
The cyclical variation in VEGF levels [4,5] is likely to
obscure or even eclipse tumor production of VEGF render-
ing serum VEGF levels unreliable as a disease marker in
breast cancer, despite having proven use in predicting
prognosis in a number of other cancers [23-25]. We did
not observe any significant difference in systemic VEGF
levels between premenopausal patients with breast cancer
and controls, supporting the evidence that the reproduc-
tive tract and hormonal milieu contribute significantly to
systemic VEGF levels in premenopausal women. Further-
more, this study did not demonstrate any significant cor-
relation between pre-operative serum VEGF levels and
tumor characteristics used in prognostication such as
grade, stage and lymph node status in the breast cancer
group, this finding is in concordance with others, who
have reported limited usefulness of VEGF as a tumour
marker in breast cancer [19,27].
Serum VEGF represents both the circulating plasma VEGF
and VEGF released from the alpha granules of circulating
platelets on coagulation [28,29]. It has been suggested
sVEGFp levels in postmenopausal breast cancer patients (n = 64) Figure 2
sVEGFp levels in postmenopausal breast cancer patients (n = 64). 2a: sVEGFp levels decreased significantly following 
tumour excision in postmenopausal breast cancer patients with an intact uterus (n = 37). *p = 0.003. 2b: sVEGFp levels did not 
decrease significantly following tumour excision in postmenopausal breast cancer patients who had previously undergone hys-
terectomy (n = 27).BMC Cancer 2008, 8:279 http://www.biomedcentral.com/1471-2407/8/279
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that platelets act as scavengers of circulating and tumour
produced VEGF in malignancy [22,30]. For this reason,
we have corrected the serum VEGF levels according to the
platelet load of the control group and the study group pre-
and post-operatively to obtain biologically relevant
sVEGFp levels.
When divided on the basis of menopausal status there was
a significant difference in circulating VEGF levels between
breast cancer patients and controls only in the postmeno-
pausal cohort.
The highest serum VEGF levels were observed in the post-
menopausal breast cancer patients. Considering the post-
menopausal decrease in ovarian function and production
of ovarian steroid hormones it is likely that tumor VEGF
production contributes largely to circulating VEGF in this
group.
The unexpected finding of higher serum VEGF levels in
women who had a previous hysterectomy implies a previ-
ously unrecognized influence of the postmenopausal
uterus on circulating VEGF levels. This finding is in con-
trast to previous reports of lower VEGF levels in postmen-
opausal patients who had undergone hysterectomy
[19,31]. Agrawal et al [31] reported significantly higher
serum VEGF levels in postmenopausal patients with an
intact uterus than those who had a previous hysterectomy,
if the patients were not using hormone replacement ther-
apy (HRT). However, in their analysis, the authors com-
pared 34 patients with an intact uterus with only 6
patients in the hysterectomy group. Interestingly, when
they compared the patients who were taking HRT, in
groups with larger numbers, it was found that patients
with an intact uterus (n = 98) had lower VEGF levels than
those who had a previous hysterectomy (n = 61). This
finding was attributed to the HRT preparations being
used; the patients with an intact uterus received combined
estrogens and progesterones, while those with a hysterec-
tomy received unopposed estrogen. However, they found
no difference in serum VEGF levels when comparing the
use of these HRT preparations in all patients. Coskun et al
[32] have reported a reduction in serum VEGF levels in
postmenopausal breast cancer patients receiving hormo-
nal therapy in the presence of a normal endometrium,
with increased circulating VEGF in patients with endome-
trial thickening. Taken together these findings suggest that
the postmenopausal uterus may indeed play an active role
in the regulation of circulating VEGF levels.
The observed reduction in circulating VEGF observed in
postmenopausal women with an intact uterus could be
mediated via decreased VEGF production or an active role
of the uterus in reducing circulating VEGF levels via
sequestration or reduction of VEGF bioactivity. The bind-
ing of free VEGF to the tyrosine kinase VEGF receptors
modulates VEGF bioavailability and may reduce soluble
VEGF levels [33]. Alternatively, there may be an active role
for the postmenopausal aromatase produced steroid hor-
mones in the regulation of circulating VEGF levels
[12,34]. Further study is required to clarify the temporal
relationship between hysterectomy and alteration in
serum VEGF levels and to elucidate the precise mecha-
nisms by which the postmenopausal uterus may reduce
circulating VEGF.
In postmenopausal breast cancer patients, where tumour-
derived VEGF was also contributing to circulating VEGF
levels, there was no difference in pre-operative VEGF lev-
els between those who had a previous hysterectomy and
those who had an intact uterus. The decrease in serum
VEGF levels post-operatively, following excision of the
tumour, was significantly more marked in the patients
with an intact uterus, mirroring the findings in the control
group and supporting the hypothesis that an intact post-
menopausal uterus has an impact on systemic VEGF lev-
els. In this manner, the presence of an intact uterus may
confer a protective effect in malignancy via a reduction in
circulating VEGF. A large cohort study addressing the
effect of previous hysterectomy on prognosis in breast
cancer patients will identify the oncologic significance of
these findings. If found to be at an increased risk of breast
cancer progression, women who have had a previous hys-
terectomy may benefit from more rigorous surveillance or
targeted therapy
Conclusion
In conclusion, serum VEGF appears to be influenced by
the presence of a postmenopausal uterus. In patients with
breast cancer this may represent a mechanism of reducing
the levels of circulating VEGF available for pathological
tumor angiogenesis, the prognostic significance of this
influence warrants further investigation.
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